文献速递艾滋病与性传播感染

美国年轻男男性行为者每日口服HIV暴露前预防:仿制药价格下可节省成本

Daily Oral HIV Pre-exposure Prophylaxis Among Young Men Who Have Sex With Men in the United States: Cost-saving at Generic Drug Price.
PubMed 文献 · Clin Infect Dis · 2024-01-01

该研究使用青少年聚焦的模拟模型,比较每年一次HIV筛查与替诺福韦酯/恩曲他滨口服暴露前预防联合每3个月HIV筛查在15-24岁高风险男男性行为者中的成本效益。结果显示,与每年筛查相比,口服暴露前预防在10年内增加质量调整生命年、减少新发感染并降低费用,在HIV年发病率≥5.1/100人年或暴露前预防年费用≤1200美元时仍可节省成本。

要点

  • 与每年筛查相比,口服暴露前预防在10年内将新发感染从37%降至30%,费用减少5000美元。
  • 当未使用暴露前预防时HIV年发病率≥5.1/100人年或暴露前预防年费用≤1200美元时,暴露前预防仍可节省成本。
  • 在终身时间跨度内,当未使用暴露前预防时HIV年发病率≥1.0/100人年时,暴露前预防可节省成本。

核心结论

  • 在美国HIV感染风险增加的年轻男男性行为者中,仿制药口服暴露前预防联合每3个月筛查与每年筛查相比可节省成本,即使在高停药率和低依从性下、在一定的HIV发病率范围内亦然。

研究设计与样本

  • 使用青少年聚焦的模拟模型,比较每年HIV筛查单独使用与替诺福韦酯/恩曲他滨口服暴露前预防联合每3个月HIV筛查在15-24岁HIV感染风险增加的年轻男男性行为者中的成本效益。

主要发现

  • 与每年筛查相比,暴露前预防在10年内增加质量调整生命年(9.58至9.67)、减少新发感染(37%至30%)并降低费用(减少5000美元)。
  • 当未使用暴露前预防时HIV年发病率≥5.1/100人年或暴露前预防年费用≤1200美元时,暴露前预防仍可节省成本。
  • 在终身时间跨度内,当未使用暴露前预防时HIV年发病率≥1.0/100人年时,暴露前预防可节省成本,在所有考察的保持率假设下均成立。
  • 当HIV年发病率≤0.1/100人年时,无论药品价格如何,暴露前预防均不具备成本效益,原因在于项目成本。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Adherence and retention concerns raise questions about the effectiveness and cost-effectiveness of oral HIV pre-exposure prophylaxis (PrEP) in young men who have sex with men (YMSM). METHODS: Using an adolescent-focused simulation model, we compared annual HIV screening alone with tenofovir disoproxil fumarate/emtricitabine-based oral PrEP with every 3-month HIV screening in YMSM (aged 15-24) at increased risk of HIV. Data derived from published sources included: age-stratified HIV incidence/100 person-years (PY) on- or off-PrEP (0.6-10.1 or 0.4-6.4), PrEP retention at 6 years (28%), transmissions by HIV RNA level (0.0-78.4/100PY) and annual costs of antiretroviral therapy ($32 000-69 000), HIV care ($3100-34 600), and PrEP program/generic drug ($900/360). Outcomes included transmissions (percent of cohort infected), quality-adjusted life-years (QALYs), costs ($), and incremental cost-effectiveness ratios ($/QALY). We explored the sensitivity of findings to variation in HIV incidence and drug prices. RESULTS: Compared with annual screening alone, PrEP would increase QALYs (9.58 to 9.67), reduce new infections (37% to 30%), and decrease costs (by $5000) over 10 years. PrEP would remain cost-saving for HIV incidence off-PrEP ≥5.1/100PY or annual PrEP price ≤$1200. Over a lifetime horizon, PrEP would be cost-saving for HIV incidence off-PrEP ≥1.0/100PY, across all retention assumptions examined. PrEP would not be cost-effective at HIV incidence ≤0.1/100PY, regardless of drug price, due to programmatic costs. CONCLUSIONS: In US YMSM at increased risk of HIV, generic oral PrEP and every-3-month screening would be cost-saving compared with annual screening alone, even with high discontinuation and low adherence, over a range of HIV incidences.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Amick AK, Eskibozkurt GE, Hosek SG, et al. Daily Oral HIV Pre-exposure Prophylaxis Among Young Men Who Have Sex With Men in the United States: Cost-saving at Generic Drug Price. Clin Infect Dis. 2024. PMID: 37823865. doi:10.1093/cid/ciad566

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。